Online Enquiry
Subscribe
Log in / New User
Retrieve Password
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Log In
|
New User Registration
|
Retrieve Password
Log In
News
TheMarket
IndustryNews
RegulatoryNews
GeneralHealth
Legal/IPRNews
Product/R&DNews
API/BulkDrugNews
PeopleintheNews
OtherNews
TopNewsWorldwide
FEATURE ARTICLES
Editorials
Commentaries
ExpertOpinions
Interviews
CaseStudies
CompanyProfiles
Editor'sPicks
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
IQVIA: Chinese Hospital Drug Market Rose 4.2% in 2023 (MAT Q4/2023)
In the fourth quarter of 2023, Chinese hospital drug sales were up 2.2% qoq, while those in MAT Q4/2023 surged 4.2% compared with MAT Q4/2022, according to a recent topli...
(3/13/2024)
The US and Chinese Biopharma Contractors (Scie... (3/18/2024)
Major Life Sciences Licensing Deal Trends in C... (3/15/2024)
Navigating China's Biologics Approval And Acce... (3/13/2024)
WuXi Became a Critical Partner to Biopharma Co... (3/13/2024)
Global Pharmaceutical Investment in Asia: A St... (3/12/2024)
Startups Raised Millions to In-license Drugs t... (3/11/2024)
China Biopharma Tracker – February 2024 (Phar... (3/10/2024)
BeiGene Still Bleeding Red Ink Despite Blockbu... (3/8/2024)
Time To 'Cut Off' US Outbound Investment in Ch... (3/7/2024)
Lessons from China's 2023 National Negotiation... (3/7/2024)
Weight Loss Drugs Threatened by US Effort to C... (3/6/2024)
China Biopharma Tracker – January 2024 (Pharm... (3/5/2024)
CDE Publicizes the List of Reference For... (3/18/2024)
Bio-Thera Solutions Partners with SteinC... (3/18/2024)
Drug R&D and Product Registration News D... (3/15/2024)
Recent Executive Moves (3/15/2024)
Unveiling Quality of Clinical Trial in C... (3/15/2024)
Biotheus and Hansoh Pharma Expand ADC Co... (3/15/2024)
Chinese Pharma Stocks Surge amid Specula... (3/15/2024)
PhIIC: Review of Prescription Drug Sales... (3/14/2024)
Sinohealth: Review of Chinese Retail Pha... (3/14/2024)
Biotech Lobby Group BIO to Sever Ties wi... (3/13/2024)
IQVIA: Chinese Hospital Drug Market Rose... (3/13/2024)
BIO Faces Criticism for Involvement in L... (3/12/2024)
CDE Issues the List of Reference Formula... (3/12/2024)
Johnson & Johnson Completes Acquisition ... (3/11/2024)
Drug R&D and Product Registration News D... (3/8/2024)
Recent Official Changes and Executive Mo... (3/8/2024)
Novo Nordisk Expects Chinese Approval fo... (3/7/2024)
China's Medical App Revolution Spearhead... (3/6/2024)
Sinohealth: Review of Chinese Retail Pharmacy Drug Sale...
PhIIC: Review of Prescription Drug Sales Trends in Chin...
IQVIA: Chinese Hospital Drug Market Rose 4.2% in 2023 (...
Review of Chinese Retail Pharmacy Market (Offline and O...
The Chinese Oncology Drug Market Projected to Grow at...
Bio-Thera Solutions Partners with SteinCares to Market ...
Chinese Pharma Stocks Surge amid Speculation of Governm...
Biotheus and Hansoh Pharma Expand ADC Collaboration
Unveiling Quality of Clinical Trial in China: from Conc...
Biotech Lobby Group BIO to Sever Ties with WuXi Amid Na...
CDE Publicizes the List of Reference Formulations for G...
CDE Issues the List of Reference Formulations for GQCE ...
CDE's Annual Review of Chinese Drug Evaluation and Regi...
US Senate Committee Approves Bill That Could Restrict C...
NMPA Announces Package Insert Revision of Synovitis For...
Shanghai's Progressive Health Insurance Initiatives: Pa...
China's Medical App Revolution Spearheaded by Ping An G...
2024 Chinese Government Work Report Highlights with Emp...
China to Expand Basic Medical Insurance Coverage for Ch...
NHSA Study Affirms Generic Metformin Effectiveness in C...
CDE Introduces a Legal Document Submission Module on th...
Narrowly Tailored U.S. Bill Targeting Chinese Biotech C...
Baricitinib's Patent Woes in China: CNIPA Invalidates O...
CNIPA to Allow Third-Party Challenges to Pharmaceutical...
State Council Issues Amended Implementing Regulations o...
India Mulls New PLI Scheme to Reduce Chinese API Depend...
FDA Criticizes Chinese API Producer for Deceptive Pract...
US Urges Indian Pharma to Distance from China for APIs ...
Chinese Researchers Makes Breakthrough with Paclitaxel ...
Crescent HiTech to Build New API Facility in Bangladesh...
Drug R&D and Product Registration News Digest March 202...
Drug R&D and Product Registration News Digest March 202...
Drug R&D and Product Registration News Digest February ...
Chinese Pharma R&D Investment Grew by Nearly 20% in 202...
Chinese Researchers Made Breakthrough in Biosynthesis o...
BioAtla and BeiGene Revise Global Deal for Novel Condit...
Pfizer to Absorb Mylan, Creating Global Generic Powerho...
PhRMA Calls for Trade Deals That Force Countries to Pay...
IQVIA: Global Pharma to Grow Slower in the Next Five Ye...
Pfizer and GSK Announce JV to Create a Global Consumer ...
Recent Executive Moves
Recent Official Changes and Executive Moves
Recent Official Changes and Executive Moves
Recent Official and Executive Moves
Recent Executive Moves
China Introduces Plan for Pudong New Area's Pilot Compr...
Upcoming Event: 2023 Pharma CI USA Conference & Exhibit...
Upcoming Event: 15th Annual Pharma Market Research Conf...
Upcoming Event: 6th International Conference on Emergin...
Upcoming Event: PHARM Connect Congress
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
2023 Order Form + Product Descripti...
WiCON Publishes the China Pharmaceu...
WiCON Publishes the China Pharmaceu...
WiCON Publishes the China Pharmaceu...
WiCON Publishes the China Pharmaceu...
WEEKLY e-ALERT(Premium)
WEEKLY e-ALERT(Basic)
GENERAL INFORMATION
TERMS/CONDITIONS OF USE
PRIVACY STATEMENT
JOIN THE MAILING LIST
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit